Would Daiichi Sankyo have to embark on change management programme to become a truly integrated hybrid business able to compete in the global pharmaceutical markets of the second 2000 decade? If so, how should its senior management address the challenge of cultural diversity in the group resulting from the Ranbaxy acquisition